Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 1;75(6):672-680.
doi: 10.1001/jamaneurol.2018.0049.

Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia

Affiliations

Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia

Diego Z Carvalho et al. JAMA Neurol. .

Abstract

Importance: Aging is associated with excessive daytime sleepiness (EDS), which has been linked to cognitive decline in the elderly. However, whether EDS is associated with the pathologic processes of Alzheimer disease remains unclear.

Objective: To investigate whether EDS at baseline is associated with a longitudinal increase in regional β-amyloid (Aβ) accumulation in a cohort of elderly individuals without dementia.

Design, setting, and participants: This prospective analysis included participants enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study in Olmsted County, Minnesota. Of 2900 participants, 2172 (74.9%) agreed to undergo carbon 11-labeled Pittsburgh compound B positron emission tomography (PiB-PET). We included 283 participants 70 years or older without dementia who completed surveys assessing sleepiness at baseline and had at least 2 consecutive PiB-PET scans from January 1, 2009, through July 31, 2016, after excluding 45 (13.7%) who had a comorbid neurologic disorder.

Main outcomes and measures: Excessive daytime sleepiness was defined as an Epworth Sleepiness Scale score of at least 10. The difference in Aβ levels between the 2 consecutive scans (ΔPiB) in Aβ-susceptible regions (prefrontal, anterior cingulate, posterior cingulate-precuneus, and parietal) was determined. Multiple linear regression models were fit to explore associations between baseline EDS and ΔPiB while adjusting for baseline age, sex, presence of the apolipoprotein E ε4 allele, educational level, baseline PiB uptake, global PiB positivity (standardized uptake value ratio ≥1.4), physical activity, cardiovascular comorbidities (obesity, hypertension, hyperlipidemia, and diabetes), reduced sleep duration, respiratory symptoms during sleep, depression, and interval between scans.

Results: Of the initial 283 participants, mean (SD) age was 77.1 (4.8) years; 204 (72.1%) were men and 79 (27.9%) were women. Sixty-three participants (22.3%) had EDS. Baseline EDS was significantly associated with increased regional Aβ accumulation in the anterior cingulate (B coefficient = 0.031; 95% CI, 0.001-0.061; P = .04), posterior cingulate-precuneus (B coefficient = 0.038; 95% CI, 0.006-0.069; P = .02), and parietal (B coefficient = 0.033; 95% CI, 0.001-0.065; P = .04) regions. Association of EDS with longitudinal Aβ accumulation was stronger in participants with baseline global PiB positivity in the anterior cingulate (B coefficient = 0.065; 95% CI, 0.010-0.118; P = .02) and cingulate-precuneus (B coefficient = 0.068; 95% CI, 0.009-0.126; P = .02) regions.

Conclusions and relevance: Baseline EDS was associated with increased longitudinal Aβ accumulation in elderly persons without dementia, suggesting that those with EDS may be more vulnerable to pathologic changes associated with Alzheimer disease. Further work is needed to elucidate whether EDS is a clinical marker of greater sleep instability, synaptic or network overload, or neurodegeneration of wakefulness-promoting centers. Early identification of patients with EDS and treatment of underlying sleep disorders could reduce Aβ accumulation in this vulnerable group.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr St Louis reports receiving research support from the Mayo Clinic Center for Clinical and Translational Science, the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH), the Michael J. Fox Foundation, and Sunovion Inc. Dr Knopman reports serving as deputy editor for Neurology; serving on a data safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer Network study; serving as an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals, and the Alzheimer’s Disease Cooperative Study; and receiving research support from the NIH. Dr Boeve reports serving as an investigator for clinical trials sponsored by GE Healthcare, FORUM Pharmaceuticals, and C2N Diagnostics; receiving royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009); serving on the scientific advisory board of the Tau Consortium; consulting for Isis Pharmaceuticals; and receiving funding from the Mangurian Foundation. Dr Lowe reports serving on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences, and Merck Research and receiving research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the National Institute on Aging (NIA) and National Cancer Institute of the NIH. Dr Roberts reports receiving research funding from the NIH and Hoffman-La Roche. Dr Mielke reports consulting for Lysosomal Therapuetics Inc and Eli Lilly and Company and receiving research funding from the NIH, Biogen, and Roche. Dr Machulda reports receiving research funding from the NIH. Dr Petersen reports receiving consulting fees from Hoffman-La Roche, Merck, Genentech, Biogen, and Eli Lilly and Company and receiving research support from the NIA of the NIH. Dr Jack reports consulting for Eli Lilly and Company and receiving funding from the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Foundation. No other disclosures reported.

Figures

Figure 1.
Figure 1.. Distribution of Longitudinal β-amyloid (Aβ) Deposition Dichotomized by Excessive Daytime Sleepiness (EDS)
Deposition of Aβ is depicted as the unadjusted difference between the second and first Pittsburgh B compound (ΔPiB) standardized uptake value ratio (SUVR) for each region according to presence of EDS. Horizontal lines indicate median; boxes, first and third quartiles; and error bars, minimum and maximum. aP < .05.
Figure 2.
Figure 2.. Regional Associations of Pittsburgh B Compound Uptake Changes (ΔPiB) With Excessive Daytime Sleepiness (EDS)
The prefrontal, anterior cingulate, posterior cingulate-precuneus and parietal regions are colored according to model estimates of regional difference between the second and first PiB scans (ΔPiB) by baseline EDS after controlling for multiple confounders in all participants (A) and participants who had global PiB positivity (standardized uptake value ratio [SUVR], ≥1.4) at baseline (B). The color scale indicates β-amyloid (Aβ) deposition increases in SUVR units as estimated by our models in every region of interest where EDS was significantly associated with ΔPiB. Regions of interest are demonstrated in a sagittal plane, from most lateral (left) to medial (right). An additional increase in Aβ accumulation is estimated in individuals with baseline global PiB positivity when compared with all individuals.

Comment in

References

    1. American Academy of Sleep Medicine The International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed Westchester, IL: American Academy of Sleep Medicine; 2005.
    1. Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65(suppl 16):12-16. - PubMed
    1. Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Prevalence of excessive daytime sleepiness in a sample of the Australian adult population. Sleep Med. 2014;15(3):348-354. - PubMed
    1. Bixler EO, Vgontzas AN, Lin HM, Calhoun SL, Vela-Bueno A, Kales A. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab. 2005;90(8):4510-4515. - PubMed
    1. Gooneratne NS, Weaver TE, Cater JR, et al. . Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc. 2003;51(5):642-649. - PubMed

Publication types

Substances